Dicyclomine Hydrochloride Recall Signals Critical CGMP Gaps for Actavis, Teva, and Cardinal Healthcare
A Class II recall of Dicyclomine Hydrochloride Tablets, USP 20 mg, initiated by Cardinal Healthcare for Teva Pharmaceuticals USA, highlights critical CGMP deviations. Products were exposed to temperatures outside labeled storage conditions, raising concerns about product integrity. This event underscores the urgent need for procurement and regulatory teams to reassess quality oversight across complex pharmaceutical supply chains.
FDA's Findings: CGMP Deviations Impacting Dicyclomine Hydrochloride Quality
The U.S. Food and Drug Administration (FDA) has overseen a Class II voluntary recall, D-0175-2024, for Dicyclomine Hydrochloride Tablets, USP 20 mg, specifically targeting Batch 3197790. This action, initiated by CARDINAL HEALTHCARE on January 26, 2022, and terminated on September 29, 2024, stems from critical Current Good Manufacturing Practice (CGMP) deviations. The primary violation cited is the exposure of these Dicyclomine Hydrochloride products to temperatures outside their labeled storage conditions. For procurement directors, this directly translates to a heightened risk of compromised product efficacy and safety. Uncontrolled temperature excursions can degrade active pharmaceutical ingredients (APIs) and excipients, potentially altering the drug's dissolution profile, stability, and therapeutic effect. Regulatory affairs heads must recognize that such deviations indicate a breakdown in environmental control systems or monitoring protocols, which are fundamental CGMP requirements. This incident, despite involving a single unit of product (NDC: 0591-0795-01), signals potential systemic vulnerabilities in the manufacturing or distribution chain that could affect broader inventory of Dicyclomine Hydrochloride and other temperature-sensitive pharmaceuticals. Proactive measures are essential to ensure that all stages of the supply chain, from manufacturing to warehousing and transit, adhere strictly to specified temperature ranges to maintain product quality and regulatory compliance.
Supply Chain Complexity: Roles of Actavis, Teva, and Cardinal Healthcare in Dicyclomine Hydrochloride Distribution
This Dicyclomine Hydrochloride recall highlights a complex multi-entity supply chain, involving Actavis Pharma, Inc. as the listed original manufacturer (ANDA085082), Teva Pharmaceuticals USA as the entity for whom the product was manufactured, and CARDINAL HEALTHCARE as the recalling firm. For supply chain VPs, this layered structure introduces significant challenges in accountability and quality oversight. The CGMP deviation, specifically temperature exposure, could have originated at any point: during manufacturing by Actavis, subsequent handling by Teva, or distribution by Cardinal Healthcare. Pinpointing the exact point of failure requires rigorous investigation and robust quality agreements between all parties. Business development executives considering partnerships within the generic pharmaceutical space must scrutinize the quality management systems and contractual obligations across the entire value chain. The nationwide USA distribution pattern for this Dicyclomine Hydrochloride product further complicates remediation, necessitating broad communication and potential retrieval efforts. This event underscores the imperative for comprehensive supplier qualification, not just of the primary manufacturer, but of all entities involved in the product's journey to market, ensuring that each link in the chain maintains stringent CGMP adherence and environmental controls for Dicyclomine Hydrochloride.
Commercial Impact and Risk Assessment for Dicyclomine Hydrochloride Procurement
While the reported quantity for this specific Dicyclomine Hydrochloride recall (Batch 3197790) was limited to '1 unit,' the underlying CGMP deviation related to temperature exposure carries significant commercial implications for procurement directors and business development executives. A Class II recall, as designated by the FDA, indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the root cause—failure to maintain labeled storage conditions—suggests a systemic risk that could affect other batches of Dicyclomine Hydrochloride or even other products manufactured or distributed through similar channels. This event necessitates an immediate risk assessment for all Dicyclomine Hydrochloride inventory sourced from Actavis Pharma, Inc. or Teva Pharmaceuticals USA, particularly any batches with similar manufacturing or distribution timelines. Regulatory affairs teams must prepare for potential increased scrutiny from the FDA on temperature control protocols and stability data for ANDA085082 and related products. The recall's nationwide USA distribution pattern means that any broader impact from similar deviations could lead to widespread supply disruptions, impacting patient access to this critical medication for irritable bowel syndrome and potentially damaging brand reputation for all involved parties.
Strategic Sourcing and Supplier Qualification for Dicyclomine Hydrochloride
Given the regulatory action against Dicyclomine Hydrochloride due to CGMP deviations, procurement teams must proactively assess their sourcing strategies. With no specific alternative suppliers named in current intelligence, the onus is on companies to identify and qualify new sources for Dicyclomine Hydrochloride API and finished dosage forms. This process is complex and time-intensive, typically involving rigorous due diligence, facility audits, and analytical testing to ensure compliance with pharmacopoeial standards and regulatory requirements. Key considerations for procurement directors include evaluating potential suppliers' historical FDA compliance records, their capacity to meet demand, and their geographic diversity to mitigate geopolitical or regional supply chain risks. Qualification timelines can span 12-24 months, encompassing technical transfers, stability studies, and regulatory submissions (e.g., prior approval supplements). Regulatory affairs heads must ensure that any new Dicyclomine Hydrochloride supplier meets all cGMP requirements, and that all necessary regulatory filings are meticulously prepared and submitted to avoid further compliance issues. This recall serves as a critical reminder that relying on a single or limited set of suppliers, especially those with documented CGMP challenges, exposes businesses to unacceptable supply chain vulnerabilities and potential market shortages for essential medicines like Dicyclomine Hydrochloride.
Navigating the Evolving Regulatory Landscape: Lessons from Recent FDA Actions
The Dicyclomine Hydrochloride recall due to CGMP deviations aligns with a broader trend of heightened FDA scrutiny on pharmaceutical manufacturing and supply chain integrity. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures and the FDA's hearing on Amgen's Tavneos market future, underscore the agency's unwavering focus on product quality and patient safety. For regulatory affairs heads, this Dicyclomine Hydrochloride incident reinforces the need for robust quality systems that extend beyond the manufacturing floor to encompass distribution and storage. Supply chain VPs must recognize that the FDA is increasingly holding all parties in the supply chain accountable for CGMP adherence. This includes ensuring proper environmental controls, data integrity, and comprehensive quality oversight for all products, including Dicyclomine Hydrochloride. Companies must implement enhanced internal audit programs and conduct more frequent, in-depth supplier audits, particularly for contract manufacturers and third-party logistics providers. Proactive engagement with regulatory intelligence, continuous monitoring of supplier performance, and immediate corrective and preventive actions (CAPAs) are no longer optional but essential to navigate this evolving regulatory landscape and safeguard market access for critical therapies.